Can two common drugs beat chemo nausea? large trial seeks answers
NCT ID NCT03367572
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 3 trial tested whether adding prochlorperazine or olanzapine to standard anti-nausea medication (netupitant/palonosetron and dexamethasone) better controls nausea and vomiting caused by chemotherapy in breast cancer patients. Over 1,300 women receiving common chemo drugs like doxorubicin or cyclophosphamide took part. The study compared nausea ratings on a 7-point scale across two chemotherapy cycles to see if the extra drugs made a meaningful difference.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Prochlorperazine or olanzapine added to netupitant/palonosetron hydrochloride and dexamethasone
- What this could lead to
- If successful, adding prochlorperazine or olanzapine could provide better relief from chemotherapy-induced nausea and vomiting for breast cancer patients.
- What could go wrong
- This is a completed phase 3 trial, so results are available but may show only modest improvement. Side effects of the additional drugs (e.g., drowsiness, dizziness) could outweigh benefits for some patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Aurora NCORP
Milwaukee, Wisconsin, 53226, United States
-
Cancer Research Consortium of West Michigan
Grand Rapids, Michigan, 49503, United States
-
Cancer Research for the Ozarks NCORP
Springfield, Missouri, 65804, United States
-
Columbus NCORP
Columbus, Ohio, 43215, United States
-
Dayton Clinical Oncology Program
Dayton, Ohio, 45459, United States
-
Decatur Memorial Hospital
Decatur, Illinois, 62526, United States
-
Geisinger Cancer Institute NCORP
Danville, Pennsylvania, 17822, United States
-
Greenville NCORP
Greenville, South Carolina, 29615, United States
-
Gulf South MU-NCORP
New Orleans, Louisiana, 70112, United States
-
Gundersen Health System
La Crosse, Wisconsin, 54601, United States
-
Hawaii MU NCORP
Honolulu, Hawaii, 96813, United States
-
Health Partners Inc
Minneapolis, Minnesota, 55454, United States
-
Michigan Cancer Research Consortium
Ann Arbor, Michigan, 48106, United States
-
Nevada Cancer Research Foundation NCORP
Las Vegas, Nevada, 89106, United States
-
Saint Vincent Hospital Cancer Center Green Bay
Green Bay, Wisconsin, 54301, United States
-
Southeast Clinical Oncology Research Program
Winston-Salem, North Carolina, 27104, United States
-
University of Rochester NCORP Research Base
Rochester, New York, 14642, United States
-
Upstate Carolina NCORP
Spartanburg, South Carolina, 29303, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Chest-Injected drug drain Cancer's fluid trap?
- A dab of gel on the breathing tube might spare surgery patients a sore throat — a trial puts it to the test.
- Can a deeper nerve block ease pain after breast surgery?
- Does breast cancer radiation harm a key immune gland? a study investigates
- A web program may ease the emotional toll of chemotherapy hair loss
- Can 3D breast imaging spot more dangerous cancers than standard mammograms?